Skip to main content
. 2018 Feb 1;16(1):42–52. doi: 10.1089/bio.2017.0079

FIG. 3.

FIG. 3.

Reported blast percentage does not explain differences in biomarker results in viable blasts and MNCs. (A) Figure shows the ratio of FLT3-ITD AR in enriched blasts relative to AR in unsorted MNCs (left y-axis, black solid line) and the reported blast percentage (right y-axis, gray solid line) in patients with FLT3-ITD mutations (N = 48, x-axis). The dashed line at 1 represents the ratio that one would expect if the AR was the same in both enriched viable blasts and unsorted MNCs. (B) Figure shows the ratio of FC of BAALC expression in viable blasts relative to unsorted MNCs (left y-axis, black solid line) and the reported blast percentage (right y-axis, gray solid line) in patients with a known blast percentage (N = 139, x-axis). The dashed line at 1 represents the ratio one that would expect if the FC was the same in both enriched viable blasts and unsorted MNCs. FC, fold change.